https://n.neurology.org/content/94/15_Supplement/4157
This an animal study but it is about ATH434. The analyses are not yet totally completed. The other interesting thing is that there are co-authors from Austria (Refolo and Stefanova), Sweden ( Zetterberg, who was also in the PBT2 Euro-study group), Heslegrave from London among our Stamler.
My point is that something "international" is happening with ATH434. This is good when there is a need to get many international study places for phase 2, perhaps.
Another abstract in AAN virtual meeting
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $4.125K | 824.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 58 | 64293651 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 29230739 | 21 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |